# Flowonix Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flowonix-medical

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.flowonix.com
- Total disclosed funding: $66M
- Latest round: Series B (Jan 4, 2021)
- Investors on record: 6

## About

Flowonix Medical, Inc. develops innovative targeted drug delivery systems, focusing on the Prometra® II Pump for precise medication administration, aiming to improve therapeutic outcomes for patients with neurological disorders.Flowonix Medical, Inc. was founded in 2005 and is based in the United States. The company specializes in developing advanced drug delivery systems, particularly the Prometra® II Pump. In January 2021, Flowonix raised USD 10.00 mn in VENTURE DEBT financing from SWK Holdings Corporation, contributing to a total amount raised of USD 2.00 mn. The firm has executed 10 deals since its inception and has operated steadily without noted pivots or changes in business strategy.Flowonix specializes in the development of targeted drug delivery systems, prominently featuring the Prometra® II Pump. This device, available in 20ml and 40ml sizes, is designed for the intrathecal delivery of medications like intrathecal baclofen, aimed at treating severe spasticity associated with neurological disorders. The pump allows for precise dosage to the spinal fluid, enhancing therapeutic outcomes while minimizing systemic side effects. Flowonix caters to healthcare providers, hospitals, and patients primarily in the United States and Europe, employing advanced technology to improve quality of life for those suffering from chronic pain and spasticity.Flowonix operates on a direct-to-consumer model, supporting healthcare providers and facilities in adopting its Prometra® II Pump. Revenue is generated through direct sales to hospitals and clinics, which deploy these systems to patients in need of targeted drug delivery. Transactions typically involve direct sales agreements allowing bulk purchases of the Prometra® II Pumps, often including training and support for healthcare professionals to ensure optimal device usage. The company’s revenue is closely tied to the adoption rates of its flagship product among healthcare providers and patients seeking effective treatment options.Flowonix Medical, Inc. intends to leverage the recent VENTURE DEBT financing of USD 10.00 mn to support its growth initiatives. The company is focusing on expanding the reach of its Prometra® II Pump into additional markets by enhancing its product offerings and increasing distribution channels. The firm plans to explore new geographic regions, particularly targeting further penetration in Europe and potential entry into Asia by 2023. Upcoming product enhancements are also in development to further optimize the efficacy of the Prometra® II Pump.

## Funding rounds

- Series B, Jan 4, 2021 — Farallon Capital Management
- Series E, Jul 17, 2014, $15M — Clarus Ventures, Hercules Capital
- Series D, May 23, 2012, $25M — Clarus Ventures, OmniCapital Group, RFT Investment Company
- Series B, Jan 19, 2009, $25M — Clarus Ventures, FatBoy Capital

## Investors

- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series B, Series D, Series E
- FatBoy Capital — Series B
- OmniCapital Group (https://capitalatlas.ai/funds/omnicapital-group) — Series D
- RFT Investment Company — Series D
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series E
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series B